A Randomized, phase II, multicenter, double-blind, place

Project: Research project

Description

A Randomized, phase II, multicenter, double-blind, placebo-controlled study evaluating the efficacy and safety of Onartuzumab (Met MAb) in combination with either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum
StatusFinished
Effective start/end date9/12/129/1/17

Funding

  • Genentech Inc.

Fingerprint

Pemetrexed
Paclitaxel
Platinum
Placebos
Safety
onartuzumab
Bevacizumab